The epidemiology of inflammatory bowel disease

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

The epidemiology of inflammatory bowel disease. / Burisch, Johan; Munkholm, Pia.

I: Scandinavian Journal of Gastroenterology, Bind 50, Nr. 8, 2015, s. 942-51.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Burisch, J & Munkholm, P 2015, 'The epidemiology of inflammatory bowel disease', Scandinavian Journal of Gastroenterology, bind 50, nr. 8, s. 942-51. https://doi.org/10.3109/00365521.2015.1014407

APA

Burisch, J., & Munkholm, P. (2015). The epidemiology of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 50(8), 942-51. https://doi.org/10.3109/00365521.2015.1014407

Vancouver

Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 2015;50(8):942-51. https://doi.org/10.3109/00365521.2015.1014407

Author

Burisch, Johan ; Munkholm, Pia. / The epidemiology of inflammatory bowel disease. I: Scandinavian Journal of Gastroenterology. 2015 ; Bind 50, Nr. 8. s. 942-51.

Bibtex

@article{bd66a377514147c2839ca3667fe506a8,
title = "The epidemiology of inflammatory bowel disease",
abstract = "BACKGROUND AND AIMS: The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing disorders of unknown aetiology. The aim of this review is to present the latest epidemiology data on occurrence, disease course, risk for surgery, as well as mortality and cancer risks.MATERIAL AND METHODS: Gold standard epidemiology data on the disease course and prognosis of patients with inflammatory bowel disease (IBD) are based on unselected population-based cohort studies.RESULTS: The incidence of ulcerative colitis (UC) and Crohn's disease (CD) has increased overall in Europe from 6.0 per 100,000 person-years in UC and 1.0 per 100,000 person-years in CD in 1962 to 9.8 per 100,000 person-years and 6.3 per 100,000 person-years in 2010, respectively. The highest incidence of IBD is found on the Faroe Islands. Overall, surgery rates have been declining over the last decades, partly due to aggressive medical therapy. Among IBD patients, mortality risk is increased by up to 50{\%} in CD when compared to the background population, but this is not the case for UC. In CD, 25 - 50{\%} deaths are disease-specific deaths, e.g. malnutrition, postoperative complications and intestinal cancer. In UC, disease-specific causes of deaths include colorectal cancer (CRC), and surgical and postoperative complications. The risk of CRC and small bowel cancer is increased two- to eightfold among IBD patients. Various subgroups carry increased risk of malignancy, e.g. those with persistent inflammation, long-standing disease, extensive disease, young age at diagnosis, family history of CRC and co-existing primary sclerosing cholangitis. The risk of extra-intestinal cancers, including lymphoproliferative disorders (LD) and intra- and extrahepatic cholangio carcinoma, is significantly higher among IBD patients.CONCLUSION: In recent years, self-management and patient empowerment, combined with evolving eHealth solutions, has utilized epidemiological knowledge on disease patterns and has been improving compliance and the timing of adjusting therapies, thus optimizing efficacy by individualizing medication in the community setting.",
keywords = "Cholangitis, Sclerosing, Colitis, Ulcerative, Colorectal Neoplasms, Crohn Disease, Denmark, Disease Progression, Europe, Female, Humans, Lymphoproliferative Disorders, Male, Postoperative Complications, Prognosis, Risk Factors, Telemedicine",
author = "Johan Burisch and Pia Munkholm",
year = "2015",
doi = "10.3109/00365521.2015.1014407",
language = "English",
volume = "50",
pages = "942--51",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - The epidemiology of inflammatory bowel disease

AU - Burisch, Johan

AU - Munkholm, Pia

PY - 2015

Y1 - 2015

N2 - BACKGROUND AND AIMS: The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing disorders of unknown aetiology. The aim of this review is to present the latest epidemiology data on occurrence, disease course, risk for surgery, as well as mortality and cancer risks.MATERIAL AND METHODS: Gold standard epidemiology data on the disease course and prognosis of patients with inflammatory bowel disease (IBD) are based on unselected population-based cohort studies.RESULTS: The incidence of ulcerative colitis (UC) and Crohn's disease (CD) has increased overall in Europe from 6.0 per 100,000 person-years in UC and 1.0 per 100,000 person-years in CD in 1962 to 9.8 per 100,000 person-years and 6.3 per 100,000 person-years in 2010, respectively. The highest incidence of IBD is found on the Faroe Islands. Overall, surgery rates have been declining over the last decades, partly due to aggressive medical therapy. Among IBD patients, mortality risk is increased by up to 50% in CD when compared to the background population, but this is not the case for UC. In CD, 25 - 50% deaths are disease-specific deaths, e.g. malnutrition, postoperative complications and intestinal cancer. In UC, disease-specific causes of deaths include colorectal cancer (CRC), and surgical and postoperative complications. The risk of CRC and small bowel cancer is increased two- to eightfold among IBD patients. Various subgroups carry increased risk of malignancy, e.g. those with persistent inflammation, long-standing disease, extensive disease, young age at diagnosis, family history of CRC and co-existing primary sclerosing cholangitis. The risk of extra-intestinal cancers, including lymphoproliferative disorders (LD) and intra- and extrahepatic cholangio carcinoma, is significantly higher among IBD patients.CONCLUSION: In recent years, self-management and patient empowerment, combined with evolving eHealth solutions, has utilized epidemiological knowledge on disease patterns and has been improving compliance and the timing of adjusting therapies, thus optimizing efficacy by individualizing medication in the community setting.

AB - BACKGROUND AND AIMS: The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing disorders of unknown aetiology. The aim of this review is to present the latest epidemiology data on occurrence, disease course, risk for surgery, as well as mortality and cancer risks.MATERIAL AND METHODS: Gold standard epidemiology data on the disease course and prognosis of patients with inflammatory bowel disease (IBD) are based on unselected population-based cohort studies.RESULTS: The incidence of ulcerative colitis (UC) and Crohn's disease (CD) has increased overall in Europe from 6.0 per 100,000 person-years in UC and 1.0 per 100,000 person-years in CD in 1962 to 9.8 per 100,000 person-years and 6.3 per 100,000 person-years in 2010, respectively. The highest incidence of IBD is found on the Faroe Islands. Overall, surgery rates have been declining over the last decades, partly due to aggressive medical therapy. Among IBD patients, mortality risk is increased by up to 50% in CD when compared to the background population, but this is not the case for UC. In CD, 25 - 50% deaths are disease-specific deaths, e.g. malnutrition, postoperative complications and intestinal cancer. In UC, disease-specific causes of deaths include colorectal cancer (CRC), and surgical and postoperative complications. The risk of CRC and small bowel cancer is increased two- to eightfold among IBD patients. Various subgroups carry increased risk of malignancy, e.g. those with persistent inflammation, long-standing disease, extensive disease, young age at diagnosis, family history of CRC and co-existing primary sclerosing cholangitis. The risk of extra-intestinal cancers, including lymphoproliferative disorders (LD) and intra- and extrahepatic cholangio carcinoma, is significantly higher among IBD patients.CONCLUSION: In recent years, self-management and patient empowerment, combined with evolving eHealth solutions, has utilized epidemiological knowledge on disease patterns and has been improving compliance and the timing of adjusting therapies, thus optimizing efficacy by individualizing medication in the community setting.

KW - Cholangitis, Sclerosing

KW - Colitis, Ulcerative

KW - Colorectal Neoplasms

KW - Crohn Disease

KW - Denmark

KW - Disease Progression

KW - Europe

KW - Female

KW - Humans

KW - Lymphoproliferative Disorders

KW - Male

KW - Postoperative Complications

KW - Prognosis

KW - Risk Factors

KW - Telemedicine

U2 - 10.3109/00365521.2015.1014407

DO - 10.3109/00365521.2015.1014407

M3 - Review

VL - 50

SP - 942

EP - 951

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -

ID: 162872964